Stay updated on Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.

Latest updates to the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added and the government-funding notice along with the prior revision entry v3.4.1 were removed; these are minor boilerplate updates that do not affect the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check20 days agoChange DetectedAdded a site-wide funding/status notice indicating government funding issues and ongoing operations; Updated the page revision from v3.4.0 to v3.4.1. These changes are minor and do not affect study data or page content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a glossary toggle to the page. Updated metadata labels (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and bumped the revision to v3.4.0.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page has removed the Statistical Analysis Plan and Study Protocol documents (and accompanying metadata) from Study Documents. Additionally, related notes about IPD sharing and FDA-regulated status were removed, reducing access to critical study details.SummaryDifference17%

- Check42 days agoChange DetectedRevision bumped from v3.3.3 to v3.3.4. No user-facing content changes observed on the Study Details page.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations section updated to include California, Maryland, Massachusetts, Nevada, Pennsylvania, Tennessee, and Texas, and the revision note updated to v3.3.3 (replacing v3.3.2).SummaryDifference0.9%

Stay in the know with updates to Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.